176 related articles for article (PubMed ID: 20544312)
1. Diabetes, anemia and CKD: Why TREAT?
Singh AK
Curr Diab Rep; 2010 Aug; 10(4):291-6. PubMed ID: 20544312
[TBL] [Abstract][Full Text] [Related]
2. Darbepoetin for the anaemia of chronic kidney disease.
Palmer SC; Saglimbene V; Craig JC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009297. PubMed ID: 24683046
[TBL] [Abstract][Full Text] [Related]
3. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
4. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
6. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
Grabe DW
Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
[TBL] [Abstract][Full Text] [Related]
7. Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.
Hayes C; Alam A; Black-Peart J; McFarlane SI
Curr Diab Rep; 2010 Apr; 10(2):87-9. PubMed ID: 20425565
[No Abstract] [Full Text] [Related]
8. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
Hudson JQ; Sameri RM
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584
[TBL] [Abstract][Full Text] [Related]
9. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill J; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R; Uno H;
Am J Kidney Dis; 2009 Jul; 54(1):59-69. PubMed ID: 19501439
[TBL] [Abstract][Full Text] [Related]
11. Anemia: To TREAT or not to TREAT--that is the question.
Wiecek A
Nat Rev Nephrol; 2010 May; 6(5):254-5. PubMed ID: 20424627
[No Abstract] [Full Text] [Related]
12. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
Scott SD
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland FR; Claggett B; Burdmann EA; Chertow GM; Cooper ME; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; McMurray JJV; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
Am J Kidney Dis; 2019 Mar; 73(3):309-315. PubMed ID: 30578152
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.
Amato L; Addis A; Saulle R; Trotta F; Mitrova Z; Davoli M
J Nephrol; 2018 Jun; 31(3):321-332. PubMed ID: 28646375
[TBL] [Abstract][Full Text] [Related]
15. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
16. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
Theilade S; Claggett B; Hansen TW; Skali H; Lewis EF; Solomon SD; Parving HH; Pfeffer M; McMurray JJ; Rossing P;
J Hum Hypertens; 2016 Jan; 30(1):46-52. PubMed ID: 25810068
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches to anemia associated with cancer and chemotherapy.
Kolesar JM
Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S8-11. PubMed ID: 12166035
[TBL] [Abstract][Full Text] [Related]
18. Anemia in chronic kidney disease: causes, diagnosis, treatment.
Nurko S
Cleve Clin J Med; 2006 Mar; 73(3):289-97. PubMed ID: 16548452
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin in kidney disease and type 2 diabetes.
Schnuelle P; Benck U; Krämer BK
N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268746
[No Abstract] [Full Text] [Related]
20. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]